Browse Category

NASDAQ:PCSA News 18 December 2025

Processa Pharmaceuticals (PCSA) Stock: Phase 2 Breast Cancer Update, 1-for-25 Reverse Split, and What Wall Street Is Watching on Dec. 18, 2025

Processa Pharmaceuticals (PCSA) Stock: Phase 2 Breast Cancer Update, 1-for-25 Reverse Split, and What Wall Street Is Watching on Dec. 18, 2025

Processa Pharmaceuticals reported preliminary Phase 2 data showing its NGC‑Cap regimen increased cancer-killing metabolite exposure and reduced toxic byproducts in metastatic breast cancer patients. The company also enacted a 1-for-25 reverse stock split effective Dec. 16. Shares saw heavy trading following the announcements.
18 December 2025

Stock Market Today

REA Group share price slides after $200m buyback plan — what ASX investors watch next

REA Group share price slides after $200m buyback plan — what ASX investors watch next

8 February 2026
REA Group shares fell 7.8% to A$168.10 after its half-year update showed a 6% rise in EBITDA and a 9% gain in core net profit, but a 24% drop in reported net profit. The company flagged softer listing volumes and announced a A$200 million buyback starting Feb. 23. Interim dividend is A$1.24 per share, ex-dividend March 3. Investors cited pressure from weaker listings and rising costs.
NAB share price in focus after Friday slide as rate rises and bank updates loom

NAB share price in focus after Friday slide as rate rises and bank updates loom

8 February 2026
National Australia Bank shares closed down 1.6% at A$43.36 on Friday after the S&P/ASX 200 fell nearly 2%, its worst session in almost a year. NAB, CBA, and Westpac will raise variable mortgage rates by 0.25% following the Reserve Bank’s hike to 3.85%. Key sector results are due from CBA on Feb. 11, Westpac on Feb. 13, and NAB on Feb. 18.
Go toTop